

Applicants: Stefan Somlo and Toshio Mochizuki  
Serial No.: 09/753,008  
Filed: January 2, 2001  
page 7 of 9

#### REMARKS

Claims 76-81 and 92-97 are pending in the subject application. Claims 79-81 and 92-94 are allowed. By this amendment, applicants have amended Claims 76 and 95 to clarify the claim language. Applicants maintain that the claim amendments do not raise an issue of new matter. Support for the amendments can be found in the previous version of the claims.

The specification has been amended to add the nucleotide sequences set forth in Figure 3 into the Sequence Listing and to add Sequence Listing identifiers to the legend for Figure 3. Applicants maintain that the amendments to the Sequence Listing and figure legend do not raise an issue of new matter.

The amendments place the application in condition for allowance or in better form for appeal. Entry of the amendments is respectfully requested.

#### Objection to the Specification

The Examiner objected to the specification because the nucleotide sequences in Figure 3 were not described in the Brief Description of the Figures.

Applicants have hereinabove amended the Sequence Listing to include the sequences set forth in Figure 3 and have amended the Brief Description of the Figures to reference the appropriate Sequence Listing identifiers (SEQ ID NO:13-15).

The content of the paper copy of the Sequence Listing attached hereto (21 pages) is the same as the content of the computer readable form (CRF) of the Sequence Listing attached hereto on floppy disk, and includes no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

Reconsideration and withdrawal of this rejection are respectfully requested.

Applicants: Stefan Somlo and Toshio Mochizuki  
Serial No.: 09/753,008  
Filed: January 2, 2001  
page 8 of 9

Rejections under 35 U.S.C. §112, Second Paragraph

Claims 76-78 and 95-97 are rejected under 35 U.S.C. §112, second paragraph, as being indefinite. The Examiner indicated that the phrase “a reference human wild-type PKD2 sequence (SEQ ID NO:6)” in step b) of Claims 76 and 95 renders the claims unclear.

Claims 76 and 95 have hereinabove been amended to recite “a reference human wild-type *PKD2* sequence set forth in SEQ ID NO:6...” Reconsideration and withdrawal of this rejection are respectfully requested.

Applicants: Stefan Somlo and Toshio Mochizuki  
Serial No.: 09/753,008  
Filed: January 2, 2001  
page 9 of 9

### CONCLUSIONS


Based on the amendments and remarks made hereinabove, reconsideration and withdrawal of the objection and rejection set forth in the September 26, 2005 Final Office Action and passage of the pending claims to allowance are respectfully requested. If there is any minor matter preventing the allowance of the subject application, the Examiner is requested to telephone the attorney listed below.

No fee is deemed necessary in connection with the filing of this reply. However, if any fee is required in connection with this reply or to preserve the pendency of the subject application, authorization is hereby given to charge the amount of any such fee to Deposit Account No. 01-1785.

Respectfully submitted,

AMSTER, ROTHSTEIN & EBENSTEIN LLP  
Attorneys for Applicants  
90 Park Avenue  
New York, New York 10016  
(212) 336-8000

Dated: December 8, 2005  
New York, New York

By   
Alan D. Miller, Reg. No. 42,889